car-γδ-t-cell – cytomed
Menu

CAR-γδ T Cell

Polygon Science-1
Daco2_Original
Daco1_Original

Manufacturing CAR-γδ T Cells (Graphic)

Unlike the conventional chimeric antigen receptor (CAR) -T cell technology that relies on the use of patient blood cells to generate highly personalized αβ T cell-based therapy for certain cancers, our CAR-γδ T cell technology utilizes healthy donor blood cells to manufacture the “off-the-shelf” CTM-N2D therapy targeting stress-induced cancer antigens that is suitable for many patients across a wide spectrum of cancers.

Manufacturing CAR-γδ T Cells (Graphic)

Donor-Blood-Flow

CAR-γδ T Cell Key Product Features (Graphic)

Cell-Report
  • Built-in receptors
  • NKG2DL-targeting CAR cells
  • Enhanced safety profile
  • "Off-the-shelf"
  • Potentially effective against a multitude of cancers
  • Broad pool of potential patients

CytoMed’s CAR-γδ T Cells vs Conventional CAR-T Cells:
Technology, Manufacture and Implications

TECHNOLOGY CONVENTIONAL CAR-T CELLS CYTOMED’S CAR-γδ T CELLS
Application setting Autologous use, applicable to a single patient only Allogeneic use, applicable to many patients
Industrial implication Highly personalized “made-to-order” product, expensive “Off-the-shelf” product, affordable
Source of starting material Patient blood cells, potential issues include:
  • Limited cell number due to leukopenia or young age;
  • Poor cell quality due to patient's conditions or previous treatments;
  • Contamination of leukaemia cells or circulating tumour cells
Healthy donor blood cells, advantages include:
  • Tested and verified cell number;
  • Reasonable cell quality;
  • Significantly lower risk of cancer cell contamination
Collection of starting material Invasive leukapheresis to collect immune cells Simple blood draw to collect blood sample
Manufacturing process A complicated manufacturing process includes:
  • Washing leukocytes out of apheresis products using a cell washer;
  • Enriching lymphocytes via counterflow centrifugal elutriation;
  • Expanding and transducing T cells using beads and lentiviral vectors
A simple manufacturing process includes:
  • Mononuclear cell isolation;
  • γδ T cell expansion;
  • mRNA electroporation
Method to install CAR Lentivirus, potential issues include:
  • Risk of secondary cancers due to insertional mutagenesis or contamination of cancer cells in the finished products;
  • Risk of long-term adverse effects due to persistence of CAR-αβ T cells;
 mRNA electroporation, advantages include:
  • Lower risk of secondary cancers;
  • Lower risk of long-term, adverse effects;
Target antigen Lineage-specific antigen(e.g. CD19), which expresses in both malignant cells and normal cells and cause “on-target off-cancer” side effect. Stress-induced antigens (e.g. NKG2DLs and phosphoantigen), which mainly express on cancer cells and reduce the risk of “on-target off-cancer” side effect.
Finished product CAR-grafted αβ T cells CAR-grafted γδ T cells
Indication For haematological malignancies so far For solid tumors and haematological malignancies
Industrial implication Highly personalized “made-to-order” product, expensive “Off-the-shelf” product, affordable